Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Biogen Inc.
  6. Company
    BIIB   US09062X1037


Business Summary
Logo Biogen Inc.
Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other anti-CD20 therapies. The Company's product candidate includes OCREVUS; Biosimilar adalimumab; Aducanumab; E2609; BIIB074; BAN2401; Opicinumab; CIRARA; BIIB061; BIIB054; BIIB067, and BIIB068.

Number of employees : 9 100 people.
Sales per Business
USD (in Million)%USD (in Million)%
Product11,38089.5%10,69286.5% -6.04%
Anti-CD20 Therapeutic Programs2,29018%1,97816% -13.65%
Other707.705.6%774.606.3% +9.45%
Sales per region
USD (in Million)%USD (in Million)%
United States9,51274.8%8,53169% -10.31%
Europe3,80429.9%3,66529.7% -3.67%
Asia432.503.4%629.605.1% +45.57%
Other629.505%619.305% -1.62%
Michel Vounatsos582017Chief Executive Officer & Director
Michael McDonnell562020Chief Financial Officer & Executive Vice President
Alfred Sandrock622020Executive Vice President-Research & Development
Mark Hernon-2017Chief Information Officer & Senior Vice President
Alphonse Galdes672019EVP-Pharmaceutical Operations & Technology
Mahalakshmi Radhakrishnan-2020Chief Medical Officer & Group Senior VP
Robert W. Pangia681997Independent Director
Nancy L. Leaming722008Independent Director
Stelios Papadopoulos722014Chairman
Brian S. Posner582008Independent Director
Members of the board
Stelios Papadopoulos722014Chairman
Robert W. Pangia681997Independent Director
Nancy L. Leaming722008Independent Director
Brian S. Posner582008Independent Director
Alexander Denner502009Independent Director
Richard Charles Mulligan, Dr.652009Independent Director
Caroline D. Dorsa602010Independent Director
Eric K. Rowinsky, Dr.632011Independent Director
Stephen A. Sherwin, Dr.712010Independent Director
Michel Vounatsos582017Chief Executive Officer & Director
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 174,354,750 149,094,000 85.5% 23,800,000 13.7% 85.5%
PRIMECAP Management Co. 15,822,066 10.4%
The Vanguard Group, Inc. 11,213,323 7.36%
Capital Research & Management Co. 10,955,000 7.19%
SSgA Funds Management, Inc. 6,992,015 4.59%
Wellington Management Co. LLP 5,781,973 3.80%
Capital Research & Management Co. (Global Investors) 5,456,600 3.58%
BlackRock Fund Advisors 3,653,008 2.40%
ClearBridge Investments LLC 3,598,673 2.36%
Icahn Associates Holding LLC 3,215,051 2.11%
Renaissance Technologies LLC 3,037,762 1.99%
Denali Therapeutics Inc. (DNLI) 13,310,24311.0%760,014,875 USD
Sage Therapeutics, Inc. (SAGE) 6,241,47310.7%467,174,254 USD
Sangamo Therapeutics, Inc. (SGMO) 24,420,15717.0%305,984,567 USD
Ionis Pharmaceuticals, Inc. (IONS) 5,750,5774.08%258,545,942 USD
Markets and indexes
- Nasdaq Global Select Market
- Nasdaq 100 / S&P 100, S&P 500
Stock Exchange Codes
- Bloomberg Code :  BIIB:US
- Reuters Code :  BIIB.O
- Datastream Code :  
Company contact information
Biogen Inc.
225 Street Binney
MA 02142 Cambridge, Massachusetts

Phone : +1 617 679-2000
Fax :
web site : https://www.biogen.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Biogen Inc.